US 10329343
Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide
granted A61KA61K2039/505A61K31/4045
Quick answer
US patent 10329343 (Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K2039/505, A61K31/4045, A61K39/3955, A61P